dementia-2016_posters-accepted-abstracts

22 / 26

Page 95
Dementia 2016
September 29-October 01, 2016
Volume 6 Issue 5(Suppl) J Alzheimers Dis Parkinsonism 2016
ISSN:2161-0460 JADP, an open access journal
conferenceseries .com
September 29-October 01, 2016 London, UK
5th International Conference on
Alzheimer’s Disease & Dementia
Ivan V Maksimovich, J Alzheimers Dis Parkinsonism 2016, 6:5(Suppl)
Monitoring the Effectiveness of Treatment of Alzheimer's Disease with Morphologically
Substantiated Dementia Scale - The Tomography Dementia Rating Scale (TDR)
Ivan V Maksimovich
Clinic of Cardiovascular Diseases named after Most Holy John Tobolsky, Russia
Background: Morphologically determined, objective assessment of disease stage and dementia severity plays an important
role in Alzheimer's disease (AD) treatment. Consequently, the Tomography Dementia Rating scale (TDR scale) based on
tomographic assessment of brain atrophic changes severity was developed and compared to the Clinical Dementia Rating scale.
The research presents results of AD stage evaluation by means of TDR scale before and after treatment.
Materials and Methods: 172 patients with different AD stages were examined. The examination included: CDR, MMSE
evaluation, cerebral scintigraphy (SG), rheoencephalography (REG), cerebral CT and MRI, morphometric definition of AD
stages (TDR), cerebral multi-gated angiography (MUGA).
For the treatment, we selected 89 patients aged 34-79 (mean age 67), 31 (34.83%) men and 58 (65.17%) women. According to
AD stages, the patients were divided:
• TDR-0 (preclinical stage) - 10 (11.24%) patients;
• TDR-1 (early stage with mild dementia, mild cognitive impairment) - 28 (31.46%) patients;
• TDR-2 (middle stage with moderate dementia, cognitive impairment sufficiently resistant) - 34 (38.20%) patients;
• TDR-3 (late stage with fairly severe dementia, severe cognitive impairment) - 17 (19.10%) patients.
Test Group - 46 (51.68%) patients - transcatheter treatment using low-energy lasers.
Control Group - 43 (48.31%) patients - conservative treatment with Memantin Rivastigmine.
Results: All 46 (100%) Test Group patients showed improvement of cerebral microcirculation, which resulted in persistent
reduction of dementia and restoring cognitive functions and allowed to transfer patients to an earlier TDR group or to withdraw
from TDR stages. Patients with TDR-1 and TDR-2 stages have shown positive effect for over 10 years. Patients with TDR-2
stage demonstrated positive effect within 4-5 years. Patients with TDR-3 stage displayed positive effect within 2-2.5 years.
Control Group patients with earlier AD stages (TDR-0, TDR-1, TDR-2) had stabilization of their condition for the period
of 6 months - 2 years, with subsequent increase of dementia and cognitive impairment. Patients with late AD stage (TDR-3)
had further increase in dementia and cognitive impairment.
Conclusions: Using morphologically, CT and MRI justified tomography dementia rating scale allows to more easily and
objectively assess the level of dementia during AD, by taking into account the severity of cerebral atrophy changes. It can be
done before, during and after treatment, regardless of the chosen treatment method; besides, the scale makes it possible to
evaluate the effectiveness of the treatment.
Biography
Ivan V. Maksimovich, MD, Head Physician of Clinic of Cardiovascular Diseases named after Most Holy John Tobolsky (Moscow, Russia) since 1993. One of the
major problems the clinic deals with is the diagnosis and treatment of various brain lesions including Alzheimer's disease. For a long time I have fully concerned
myself with the diagnosis and treatment of Alzheimer's disease. Over the past 15 years I have published over 60 scientific works on this subject. ISTAART member,
ESC member, EAPCI member, WSO member, ESO member, EPA member.